Having trouble accessing articles? Reset your cache.

Regeneron’s new biologic boosts small molecule binding

Regeneron’s biologic with deep binding pocket beats conventional antibodies at trapping small molecules

Regeneron has expanded its suite of drug discovery technologies by developing a new type of biologic capable of binding small molecules better than conventional antibodies.

The company has been seeking new technologies -- such as nucleic acid therapies and cell therapies -- to take on targets

Read the full word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers